Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New eczema drug shows promise in Mid-Stage trial

NCT ID NCT06700499

Disease control Sponsor: Akeso Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new drug, AK120, in 450 adults with moderate to severe atopic dermatitis (eczema). The main goal was to check for side effects and see how well the drug works. Researchers measured changes in eczema severity using standard skin scores.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

450 people

The number who actually took part.

Started

Jul 2024

Finished

Sep 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Male or female subjects aged ≥18≤75 years old. 2. Atopic dermatitis (AD) diagnosed at least half a year before screening. 3. Subject with EASI score ≥16, IGA ≥ 3, BSA ≥ 10% at screening and baseline. 4. Subjects who are suitable for continue using biological treatment assessed by investigator Exclusion Criteria: 1. Acute onset of AD within 4 weeks before drug administration. 2. The accompany disease have been assessed by the investigators during screening period as unsuitable for participation in this study. 3. Any history or symptoms of malignant tumors in any organ within 5 years prior to screening, regardless of whether treatment has been received and whether there are signs of recurrence or metastasis 4. Have a known or suspected history of immunosuppressive diseases, including a history of invasive infections. 5. Having undergone or planned major surgery within 4 weeks prior to drug administration, or unable to fully recover from surgery prior to drug administration. 6. any medical or psychological condition that puts subjects at risk or may affect the study results assessed by investigators.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atopic dermatitis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atopic eczema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atopic dermatitis

Contacts and locations

Locations

  • Affiliated Hangzhou First People's Hospital

    Hangzhou, Zhejiang, China

  • Affiliated Hospital of Chengde Medical University

    Chengde, Hebei, China

  • Affiliated Hospital of Jiangsu University

    Zhenjiang, Jiangsu, China

  • Affiliated Hospital of Nantong University

    Nantong, Jiangsu, China

  • Anyang District Hospital

    Anyang, Henan, China

  • Beijing Luhe Hospital Affiliated to Capital Medical University

    Beijing, Beijing Municipality, China

  • Cangzhou People's Hospital

    Cangzhou, Hebei, China

  • Changde First People's Hospital

    Changde, Hunan, China

  • Guangdong Provincial Dermatology Hospital

    Guangzhou, Guangdong, China

  • Guangdong Provincial People's Hospital

    Guangzhou, Guangdong, China

  • Hangzhou Third People's Hospital

    Hangzhou, Zhejiang, China

  • Jiaxing Second Hospital

    Jiaxing, Zhejiang, China

  • Jingzhou Central Hospital

    Jingzhou, Hubei, China

  • Liuzhou People's Hospital

    Liuzhou, Guangxi, China

  • Ningbo No.2 Hospital

    Ningbo, Zhejiang, China

  • Peking University Third Hospital

    Beijing, Beijing Municipality, China

  • People Hospital of Xingtai

    Xingtai, Hebei, China

  • Qilu Hospital of Shandong University

    Jinan, Shandong, China

  • Qujing No.1 Hospital

    Qujing, Yunnan, China

  • Renmin Hospital of Wuhan University

    Wuhan, Hubei, China

  • Sanmenxia Central Hospital

    Sanmenxia, Henan, China

  • Second people's Hospital of Shenzhen

    Shenzhen, Guangdong, China

  • Shandong First Medical University Affiliated Dermatology Hospital

    Jinan, Shandong, China

  • Shanghai Skin Disease Hospital

    Shanghai, Shanghai Municipality, China

  • Shanghai Yueyang Integrated Traditional Chinese Medicine and Western Medicine Hospital

    Shanghai, Shanghai Municipality, China

  • Shenzhen Hospital of University of Hong Kong

    Shenzhen, Guangdong, China

  • Shijiazhuang Hospital of Traditional Chinese Medicine

    Shijiazhuang, Hebei, China

  • Sichuan Provincial People's Hospital

    Chengdu, Sichuan, China

  • Taiyuan Central Hospital

    Taiyuan, Shanxi, China

  • Taizhou Central Hospital

    Taizhou, Zhejiang, China

  • The Affiliated Hospital of Inner Mongolia Medical College

    Hohhot, Inner Mongolia, China

  • The Affiliated Hospital of Yanbian University Yanbian Hospital

    Yanbian, Jilin, China

  • The First Affiliated Hospital of Fujian Medical University

    Fuzhou, Fujian, China

  • The First Affiliated Hospital of Kunming Medical University

    Kunming, Yunnan, China

  • The First Hospital of Hebei Medical University

    Shijiazhuang, Hebei, China

  • The First Hospital of Jiaxing

    Jiaxing, Zhejiang, China

  • The Second Affiliated Hospital of Henan University of Science and Technology

    Luoyang, Henan, China

  • The Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine

    Tianjin, Tianjin Municipality, China

  • The Second Affiliated Hospital of Xiamen Medical College

    Xiamen, Fujian, China

  • The Second Affiliated Hospital of Xingtai Medical College

    Xingtai, Hebei, China

  • The Second Affiliated Hospital of Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China

  • The Second Hospital & Clinical Medical School, Lanzhou University

    Lanzhou, Gansu, China

  • Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital

    Tianjin, Tianjin Municipality, China

  • Wuhan No.1 Hospital

    Wuhan, Hubei, China

  • Wuxi People's Hospital

    Wuxi, Jiangsu, China

  • XiangYa Hospital CentralSouth University

    Changsha, Hunan, China

  • Xinjiang Uygur Municipal People's Hospital

    Ürümqi, Xinjiang, China

  • Xiyuan Hospital of CACMS

    Beijing, Beijing Municipality, China

  • Yantai Yuhuangding Hospital

    Yantai, Shandong, China

  • Yueyang Central Hospital

    Yueyang, Hunan, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.